In patients with EGFR-mutated NSCLC, the HERTHENA-Lung01 phase II trial evaluated patritumab deruxtecan (HER3-DXd) in patients who progressed with EGFR TKI therapy and platinum chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.